May 24, 2012

CLOSE

To subscribe to updates from this journal click Confirm. Updates will be displayed in your default RSS reader.

Produced and published by Remedica Medical Education and Publishing Limited.

» Contact us

Inflammatory Bowel Disease Monitor

» Advanced search

Please note that only limited free access to this journal is available in your country or territory.

To access the full content of this article you must purchase it (US$9.49). After payment of this one-off fee, you will gain unrestricted online access to the article and a PDF version sent to your email.

As part of our special introductory offer, after purchasing this article you will have unrestricted access to all the articles in this issue for free!

Registered users can purchase/access the article by logging in below. To register for free click here

Registered users login here:

Email Address:
Password:

If you have forgotten your password click here


0 rating

Fecal Markers of Disease Recurrence in IBD

Omar Khan, MD, and Laura Harrell, MD, MS

The ability to assess disease recurrence in patients with IBD is a complicated task. Endoscopy with mucosal biopsy remains the gold standard for assessing disease activity, while radiology examinations and laboratory tests play supportive roles. Cumulative radiation exposure, the risks of repeated, invasive endoscopic examinations, and poor testing characteristics of nonspecific, serological markers demonstrate how difficult it is to perform a simple assessment of disease activity. In recent years, fecal biomarkers have emerged as potential markers of disease activity. Through direct contact with the intestinal mucosa, these markers may be more specific markers of intestinal inflammation. In this review, we discuss fecal biomarkers and their role assessing recurrence of disease after medically and surgically induced remission. Inflamm Bowel Dis Monit 2010;11(1):15–21.

Please login or register to continue reading this article

Login/Register

Post Page On

RELATED ARTICLES

Cytokine Regulation of Gut Inflammation in IBD

Thomas T MacDonald, PhD, FRCPath, FMedSci¹, Iona Bell, MD¹, and Giovanni Monteleone, MD²

Inflammatory Bowel Disease Monitor

The Safety of Thiopurines: New Data, New Decisions

Laurent Beaugerie, MD, Harry Sokol, MD, Philippe Seksik, MD, and Jacques Cosnes, MD

Inflammatory Bowel Disease Monitor

Managing Low-Grade Dysplasia

Aelaf D Worku, MD, and Thomas A Ullman, MD

Inflammatory Bowel Disease Monitor

Clostridium difficile and IBD

David G Binion, MD

Inflammatory Bowel Disease Monitor

Digestive Disease Week 2010: An Update on IBD Clinical Research

Garret Cullen, MD, and Adam Cheifetz, MD

Inflammatory Bowel Disease Monitor

RELATED ARTICLES IN PUBMED

Genetic and genomic predictors of anti-TNF response.

Changes in immunohistochemical levels and subcellular localization after therapy and correlation and colocalization with CD68 suggest a pathogenetic role of Hsp60 in ulcerative colitis.

Monitoring 6-thioguanine nucleotide concentrations in Japanese children and adolescents with inflammatory bowel disease.

Prediction of 6-thioguanine nucleotides levels in Japanese patients with inflammatory bowel diseases during long-term thiopurine administration.

Higher levels of CCL20 expression on peripheral blood mononuclear cells of chinese patients with inflammatory bowel disease.

Azathioprine: when less is more.

LATEST ARTICLES

Leading Articles
- Managing Low-Grade Dysplasia
  
  Aelaf D Worku, MD, and Thomas A Ullman, MD
  
  The Dr Henry D Janowitz Division of Gastroenterology, Mount Sinai School of Medicine, New York, NY, USA
  
  The known colitis–dysplasia–carcinoma sequence allows for gastroenterologist-endoscopists to identify early neoplastic changes and perform maneuvers that will result in improved outcomes for patients. The key maneuvers that can lead to improved cancer-free survival are, firstly, endoscopic removal of dysplasia using standard polypectomy techniques; and, secondly, timely colectomy for patients with insufficiently resected dysplasia.
- Clostridium difficile and IBD
  
  David G Binion, MD
  
  Inflammatory Bowel Disease Center, Division of Gastroenterology, Hepatology and Nutrition, UPMC Presbyterian Hospital, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
  
  The anaerobic spore-forming bacillus, Clostridium difficile (C difficile), has emerged as a serious infection over the past decade, more than doubling in incidence in North American medical centers.
- Fecal Markers of Disease Recurrence in IBD
  
  Omar Khan, MD, and Laura Harrell, MD, MS
  
  Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago Medical Center, Chicago, IL, USA
  
  The ability to assess disease recurrence in patients with IBD is a complicated task. Endoscopy with mucosal biopsy remains the gold standard for assessing disease activity, while radiology examinations and laboratory tests play supportive roles.
Clinical Reviews
Meeting Reports
- Digestive Disease Week 2010: An Update on IBD Clinical Research
  
  Garret Cullen, MD, and Adam Cheifetz, MD
  
  New Orleans, LA, USA, May 1–5, 2010
  Harvard Medical School, and Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, Boston, MA, USA
  
  Digestive Diseases Week (DDW) 2010 was held from May 1–5 in New Orleans, LA, USA. More than 13 000 participants attended this year’s meeting. The clinical aspects of the immunology and IBD section were comprised of 378 abstracts, of which 64 were oral presentations. The highlights of the abstracts relating to clinical IBD research are summarized in this report.
- Digestive Disease Week 2010: An Update on IBD Basic Science
  
  Paul Henderson, MB ChB, MRCPCH
  
  New Orleans, LA, USA, May 1–5, 2010
  Department of Child Life and Health, and Gastrointestinal Unit, Molecular Medicine Centre, University of Edinburgh, UK
  
  Digestive Disease Week (DDW) 2010 brought together both clinicians and basic scientists to allow the presentation and discussion of novel aspects of gastrointestinal (GI) and liver diseases. This report summarizes the highlights of mostly unpublished basic research in the field of IBD presented during the meeting.

Our most popular articles

READ

Is Diet Involved in the Etiology of Ulcerative Colitis and Crohn’s Disease? A Review of the Experimental and Epidemiological Literature
(Volume 12 Issue 1 / Leading Articles)
Adherent–Invasive Escherichia coli: Role in Crohn’s Disease Pathogenesis
(Volume 10 Issue 3 / Leading Articles)
Diagnosis and Management of Anemia in IBD
(Volume 11 Issue 4 / Leading Articles)
Enteral Nutrition in IBD
(Volume 09 Issue 4 / Leading Articles)
The Safety of Thiopurines: New Data, New Decisions
(Volume 10 Issue 4 / Leading Articles)
Metabolomics and IBD
(Volume 12 Issue 2 / Leading Articles)

British Society of Gastroenterology Annual Meeting 2011
(Volume 11 Issue 4 / Meeting Reports)
1st British Society of Gastroenterology Supraregional Meeting
(Volume 12 Issue 2 / Meeting Reports)

Is Diet Involved in the Etiology of Ulcerative Colitis and Crohn’s Disease? A Review of the Experimental and Epidemiological Literature
(Volume 12 Issue 1 / Leading Articles)
Metabolomics and IBD
(Volume 12 Issue 2 / Leading Articles)
Epidemiology
(Volume 12 Issue 2 / Clinical Reviews)

Home | Issues | Search | Paper of the Month | About Journal | Editorial Board | Video/Audio | Reader Surveys | Register | Submit Content | Contact us

© 2012 Remedica Medical Education and Publishing Disclaimer

CLOSE

© Remedica 2012. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of the copyright owners. While every effort is made by the publishers and editorial board to see that no inaccurate or misleading data, opinions, or statements appear in this journal, they wish to make it clear that the material contained in the publication represents a summary of the independent evaluations and opinions of the authors and contributors. As a consequence, the board, publishers, and any supporting company accept no responsibility for the consequences of any such inaccurate or misleading data or statements. Neither do they endorse the content of the publication or the use of any drug or device in a way that lies outside its current licensed application in any territory. For detailed information on any drugs or devices discussed in this publication, readers are advised to consult the manufacturer’s prescribing information.

Produced and published by Remedica Medical Education and Publishing Limited.